Masahiro Sugita
Director/Board Member bij HORIBA, LTD.
Profiel
Masahiro Sugita is an Independent Outside Director at The 77 Bank, Ltd.
since 2013 and at Horiba Ltd.
since 2006.
He previously worked as General Director-International Department at Bank of Japan, Director-Overseas Investment Research Institute at Export-Import Bank of Japan, and Auditor at MSD (Japan) Co., Ltd.
Actieve functies van Masahiro Sugita
| Bedrijven | Functie | Begin |
|---|---|---|
| HORIBA, LTD. | Director/Board Member | 18-01-2010 |
| THE 77 BANK, LTD. | Director/Board Member | 01-06-2013 |
Eerdere bekende functies van Masahiro Sugita
| Bedrijven | Functie | Einde |
|---|---|---|
| BANK OF JAPAN | Corporate Officer/Principal | - |
| Export-Import Bank of Japan | Corporate Officer/Principal | - |
MSD (Japan) Co., Ltd.
 MSD (Japan) Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., MSD (Japan) Co., Ltd. is a company that focuses on Japanese domestic development pipeline. The private company is based in Tokyo, Japan. The company's description states that it is a page of the clinical trial guide, which suggests that it is involved in the development and testing of new pharmaceutical products. | Comptroller/Controller/Auditor | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| THE 77 BANK, LTD. | Finance |
| HORIBA, LTD. | Producer Manufacturing |
| BANK OF JAPAN | Government |
| Bedrijven in privébezit | 2 |
|---|---|
MSD (Japan) Co., Ltd.
MSD (Japan) Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., MSD (Japan) Co., Ltd. is a company that focuses on Japanese domestic development pipeline. The private company is based in Tokyo, Japan. The company's description states that it is a page of the clinical trial guide, which suggests that it is involved in the development and testing of new pharmaceutical products. | Health Technology |
| Export-Import Bank of Japan | Finance |
